Checkmate Pharmaceuticals Total Revenue

As of the most recent data (March 2022), CMPI shows a total revenue of $0. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CMPI's total revenue is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Checkmate Pharmaceuticals is outperforming or lagging.

The Healthcare sector average total revenue is about $110B. Checkmate Pharmaceuticals is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CMPI stacks up against individual peers as well.

Tracking CMPI's total revenue over time shows whether Checkmate Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Checkmate Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $0) with ownership activity and broader fundamentals.